The interaction of the steroid anaesthetic agent CT1341 with selected muscle relaxants and volatile agents has been investigated in man. In four patients the effect at the neuromuscular junction was examined. No effect was seen with CT1341 alone and there was no clinically significant interaction with tubocurarine, pancuronium or suxamethonium. A further forty patients in six groups were anaesthetized using CT1341 and either pancuronium or tubocurarine with controlled respiration. One of the volatile agents, halothane, trichloroethylene or methoxyflurane, was then administered and the resulting effect on electrocardiogram, systolic and diastolic blood pressure, pulse rate and nasopharyngeal temperature noted. Three patients given methoxyflurane developed a marked sinus tachycardia which could be evidence of drug interaction. No other effect was observed.
Preliminary studies of the action of the new steroid induction agent CT1341 in man have recently been reported (Campbell et al., 1971) . The present report is of further investigations in man designed to define the interaction of the new drug, if any, with some selected muscle relaxant drugs and volatile agents. No adverse effects were found in earlier animal studies where CT1341 was used along with some common anaesthetic agents (Child et al., 1971 ) and the conclusion from this work was that the drug might be expected to fit safely into the usual anaesthetic sequence employed clinically.
METHODS AND RESULTS

Muscle relaxant investigations.
An initial study was carried out to determine whether CT1341 itself produced any degree of neuromuscular blockade. Following this, CT1341 was injected during the recovery phase of myoneural block induced by tubocurarine, pancuronium and suxamethonium respectively.
Four fit patients for surgery on the lower limbs were premedicated with papaveretum 20 mg and hyoscine 0.4 mg. Anaesthesia was induced with thiopentone (2.5 per cent) and tracheal intubation performed with suxamethonium 50 mg. Anaesthesia was maintained with nitrous oxide/oxygen and 0.5 per cent halothane and ventilation mechanically assisted so as to maintain an arterial carbon dioxide tension of 35-45 mm Hg and an acceptable arterial oxygen tension in each patient throughout the period of investigation. Direct measurements of pH, Pco 3 and PCL, were made on each sample using the Instrumentarium Laboratories' electrode system.
The right arm was placed on an arm-board and two 25-mm gauge disposable hypodermic needles inserted subcutaneously, one over the ulnar nerve at the elbow and the other over the ulnar nerve at the wrist. The thumb was arranged on a button-extension attached to a Grass straingauge transducer (type FT10). This technique is a modification of that employed by Walts, Lebowitz and Dillon (1968) . The transducer was connected to a Devices pre-amplifier unit and thence to a Devices M2 recorder, the paper speed of which was set at 0.1 mm/sec. The supramaximal stimulus to the ulnar nerve was delivered from a Grass nerve stimulator (model S4) in pulses of 0.2 m/sec width at a rate of 0.1 Hz.
When stable anaesthesia was achieved in the first patient CT1341 in a dose of 0.05 ml/kg was injected intravenously over a period of 30 sec. The muscle twitch recording was then studied over a period of 10 min. No myoneural block was produced by the steroid agent. The following three patients were anaesthetized in the same way. In the first of these, myoneural block was induced with tubocurarine (0.5 mg/kg) and during the recovery phase CT1341 in a dose of 0.05 ml/kg was injected and the muscle twitch again observed till full recovery. Similar observations were made on the second patient in whom myoneural block was induced with pancuronium (0.1 mg/kg) and again on the third patient in whom a suxamethonium block was produced. No myoneural block was observed when CT1341 was used alone and there was no effect on pancuronium-or suxamethonium-induced blockade. There was a suggestion of the slightest transient delay in recovery when the steroid was used along with tubocurarine, although this is highly unlikely to have any clinical significance. It is possible that this apparent effect was seen as a result of the haemodynamic changes known to occur following the injection of CT1341. The muscle twitch recording referred to is shown in figure 1. 
Interaction with volatile anaesthetic agents.
Following the above investigations, it was decided to study the use of the steroid agent during surgery when used along with a muscle relaxant and either halothane, trichloroethylene or methoxyflurane. Six groups of otherwise fit patients mainly for abdominal surgery, a total of 40, were anaesthetized in the following manner (table I) . A standard premedication of papaveretum 10 mg and hyoscine 0.4 mg was given intramuscularly to every patient 1 hour prior to anaesthesia. Induction of anaesthesia was with CT1341 at a dose level of 0.1 ml/kg. This relatively high dosage range was chosen to ensure that any possible drug interactions or side effects would be more likely to be revealed. Following induction, anaesthesia was maintained widi nitrous oxide/oxygen and either tubocurarine (0.5 mg/kg) or pancuronium (0.1 mg/kg) and the trachea intubated. Ventilation was controlled with a mechanical ventilator adjusted to maintain the arterial carbon dioxide tension between 35 and 45 rnm Hg and the arterial oxygen tension above 90 mm Hg. Direct measurements of pH, and Pco 3 and Po, were made using the Instrumentarium Laboratories' electrode system. In only a small proportion of patients was it found impossible to achieve these levels (table II). In these instances it was not thought that this in fact invalidated the other observations. A continuous intravenous infusion of CT1341 was maintained throughout anaesthesia at a mean dose rate of 0.004-0.006 ml/kg/min. When anaesthesia was judged to be stable, one of three volatile agents, 0.5 per cent halothane, 0.5 per cent trichloroethylene or 0.5 per cent methoxyflurane, was introduced to the circuit for a predetermined period of time (10 min, 20 min and 20 min respectively). The resulting effects on the e.c.g., systolic and diastolic blood pressure, pulse rate and nasopharyngeal temperature were observed during the control period prior to introduction of the volatile agent, during inhalation of the agent and during recovery. The blood pressure was measured using a brachial stethoscope and standard mercury sphygmomanometer. Pulse rate was measured at the wrist over a period of 1 minute, while the nasopharyngeal temperature was measured by thermistor probe and a previously calibrated electrothermometer.
Table HI details the results of these studies. The six groups of patients were, broadly speaking, comparable in that although the proportion of males and females varied in each group, there were no significant differences between the groups in mean age or mean weight.
Heart rate effects. As reported in earlier studies in man, a sinus tachycardia usually followed in- This table shows the details of the 40 patients studied in the six separate groups. Although there were differences in the ratio of male to female patients in the groups, there were no significant differences in mean age or mean weight between the groups. duction of anaesthesia with CT1341. In six patients, however, the heart rate slowed from the pre-anaesthetic level during the control period. Three of these patients were in Group C (trichloroethylene with tubocurarine). When this group therefore, was compared with Group D (trichloroethylene with pancuronium) the difference between the mean control heart rates was significant (P<0.05) and the difference between the mean heart rates during exposure to the trichloroethylene was highly significant (P<0.01). The initial tachycardia produced by CT1341 would appear to be uninfluenced by the choice of either tubocurarine or pancuronium. During the test period of exposure to the individual volatile agents the heart rate tended to slow or remain unchanged as compared with the control. There were three exceptions to this (Case Nos. 25, 35 and 38) , all being patients who received methoxyflurane. In these patients the sinus tachycardia appeared to be enhanced during the test period, returning to the control level on withdrawal of the methoxyflurane. This observaation was not, however, statistically significant but it is intended to examine this possible drug interaction more closely in a separate investigation.
No.
In two patients (Case Nos. 19 and 40) who received methoxyflurane and trichloroethylene respectively along with pancuronium, there was a period of marked bradycardia immediately postoperatively. This responded to further atropine administration and was judged to be due to the vagotonic effect of neostigmine.
Effects on systemic blood pressure. Whilst in earlier studies a consistent fall in blood pressure was noted 30 sec following completion of the CT1341 injection, in the present series this transient effect was not observed due to the timing of the measurements. During the control measurements the blood pressure tended to rise from the pre-anaesthetic level. This seemed to coincide with the level of surgical stimulation (fig. 2, Case No. 18 ). In one case, however, not included in this series, infusion of CT1341 was stopped soon after induction of anaesthesia and the investigation abandoned when the blood pressure fell precipitately from a resting level of 160 mm Hg systolic to 80 mm Hg systolic. The operation continued and recovery was uneventful. In all groups of patients the introduction of the volatile agent resulted in a reversal of this hypertensive effect and the blood pressure returned to near the preanaesthetic level. Only in Group F (methoxyflurane with pancuronium) were these changes statistically significant. The effect of surgical stimulation on the systemic blood pressure during CT1341 administration.
•-X Systolic blood pressure.
A.-A Diastolic blood pressure. Pulse rate.
General comments.
Induction of anaesthesia was smooth, rapid and uneventful in all cases, although some muscle twitching was noted in three patients. In most patients marked dilatation of the pupils was observed immediately following induction. Tracheal intubation was easily performed, particularly in the patients to whom pancuronium had been given. No alterations in nasopharyngeal temperature were noted in any patient during the investigation. The surgical conditions obtained throughout were excellent and recovery from anaesthesia uncomplicated, although delay in recovery of consciousness was noted in patients receiving methoxyflurane when the surgery had terminated earlier than expected. Reversal of the muscle relaxant was achieved readily in every case with a dose of neostigmine not exceeding 2.5 mg along with atropine sulphate 1.2 mg. No nausea or vomiting was observed postoperatively, and there was no evidence of thrombophlebitis attributable to CT1341.
DISCUSSION
It was predicted from the animal investigations conducted by Child and others (1971) that CT1341 should fit safely into the commonly employed clinical anaesthetic sequences. The present examination of this new agent suggests that this is probably the case. In the initial muscle relaxant studies there was no evidence of drug interaction although a possible transient delay in the decay of tubocurarine block was observed. The second half of this investigation confirmed that there was no interaction in that neuromuscular blockade was easily reversed in every patient.
No unforeseen drug interactions were encountered when CT1341 was used in conjunction with the volatile agents, with the possible exception of methoxyflurane. The increase in heart rate in some patients when this agent is employed is at present unexplained and deserves further investigation. Since a relatively high dose level of CT1341 was employed at induction, the subsequent continuous infusion of the drug ensured that its effects were maximal when the volatile agent under test was introduced. This constituted a fairly severe test of CT1341 and it is not expected that this dose level would be required in clinical practice. The incidence of muscle "twitching" observed in the earlier studies in man and again in some patients during the present investigation would seem to be possibly due to a response to surgical stimulation rather than an excitatory effect This matter is, however, still open to debate and further work is required to elucidate the problem and to discover whether the phenomenon is dose-related or not. It is not yet known whether CT1341 is analgesic in the dose range employed.
In the present study the premedication was standardized so that no comment can be made on the possible modifying effects of other agents in common use for premedication on CT1341. Atropine has not been employed so far in premedication since CT1341 itself produces a marked tachycardia and as a result it may be necessary to administer more than the usual dose of atropine with neostigmine when reversing the muscle relaxant. Further examination of the steroid with other combinations of premedicant drugs is desirable.
